Cite
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
MLA
Barlesi, Fabrice, et al. “Health-Related Quality of Life in KEYNOTE-010: A Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC.” Journal of Thoracic Oncology, vol. 14, no. 5, May 2019, pp. 793–801. EBSCOhost, https://doi.org/10.1016/j.jtho.2019.01.016.
APA
Barlesi, F., Garon, E. B., Kim, D.-W., Felip, E., Han, J.-Y., Kim, J.-H., Ahn, M.-J., Fidler, M. J., Gubens, M. A., de Castro, G., Surmont, V., Li, Q., Deitz, A. C., Lubiniecki, G. M., & Herbst, R. S. (2019). Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC. Journal of Thoracic Oncology, 14(5), 793–801. https://doi.org/10.1016/j.jtho.2019.01.016
Chicago
Barlesi, Fabrice, Edward B. Garon, Dong-Wan Kim, Enriqueta Felip, Ji-Youn Han, Joo-Hang Kim, Myung-Ju Ahn, et al. 2019. “Health-Related Quality of Life in KEYNOTE-010: A Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC.” Journal of Thoracic Oncology 14 (5): 793–801. doi:10.1016/j.jtho.2019.01.016.